<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.clinicalmolecularallergy.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Clinical and Molecular Allergy - Latest Articles</title>
        <link>http://www.clinicalmolecularallergy.com</link>
        <description>The latest research articles published by Clinical and Molecular Allergy</description>
        <dc:date>2010-08-11T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/12" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/11" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/10" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/9" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/8" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/7" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/6" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/5" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/4" />
                                <rdf:li rdf:resource="http://www.clinicalmolecularallergy.com/content/8/1/3" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/12">
        <title>The increase of plasma galectin-9 in a patient with insulin allergy: a case report</title>
        <description>Allergic reaction to insulin is known to be associated with eosinophilia and hyper IgE. Recent report showed that eosinophilia is related with the increased synthesis of galectin-9 (GAL-9) and osteopontin (OPN). Here, we examined plasma levels of GAL-9 and OPN first time in a case of 65-year old patient with insulin allergy. Insulin aspart &amp; insulin aspart 30 mix were given to the patient and an elevation of the eosinophil count (8440/&#956;l, 17.6 fold) and a moderate increase of IgE (501 U/ml, reference range: 10-350 U/ml), eotaxin-3 (168 pg/ml, 2 fold), histamine (0.95 ng/ml, 5.3 fold) were found 33 days later. The plasma levels of GAL-9 and OPN were 22.5 and 1.7 fold higher than the cut-off point, respectively. After one month cessation of insulin therapy, elevations of the eosinophil count (3,480/&#956;l; 7.3 fold), and OPN (1.4 fold) still occurred but the GAL-9 levels became normal. Therefore, we noted the increases of GAL-9 and OPN in plasma for the first time in a patient with insulin allergy and propose that GAL-9 reflects the conditions of allergy more accurately.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/12</link>
                <dc:creator>Haorile Chagan-Yasutan</dc:creator>
                <dc:creator>Beata Shiratori</dc:creator>
                <dc:creator>Umme Siddiqi</dc:creator>
                <dc:creator>Hiroki Saitoh</dc:creator>
                <dc:creator>Yugo Ashino</dc:creator>
                <dc:creator>Tomohiro Arikawa</dc:creator>
                <dc:creator>Mitsuomi Hirashima</dc:creator>
                <dc:creator>Toshio Hattori</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:12</dc:source>
        <dc:date>2010-08-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-12</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2010-08-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/11">
        <title>Cord blood versus age 5 mononuclear cell proliferation on IgE and asthma</title>
        <description>Background:
Fetal immune responses following exposure of mothers to allergens during pregnancy may influence the subsequent risk of childhood asthma. However, the association of allergen-induced cord blood mononuclear cell (CBMC) proliferation and cytokine production with later allergic immune responses and asthma has been controversial. Our objective was to compare indoor allergen-induced CBMC with age 5 peripheral blood mononuclear cell (PBMC) proliferation and determine which may be associated with age 5 allergic immune responses and asthma in an inner city cohort.
Methods:
As part of an ongoing cohort study of the Columbia Center for Children&apos;s Environmental Health (CCCEH), CBMCs and age 5 PBMCs were cultured with cockroach, mouse, and dust mite protein extracts. CBMC proliferation and cytokine (IL-5 and IFN-&#947;) responses, and age 5 PBMC proliferation responses, were compared to anti-cockroach, anti-mouse, and anti-dust mite IgE levels, wheeze, cough, eczema and asthma.
Results:
Correlations between CBMC and age 5 PBMC proliferation in response to cockroach, mouse, and dust mite antigens were nonsignificant. Cockroach-, mouse-, and dust mite-induced CBMC proliferation and cytokine responses were not associated with allergen-specific IgE at ages 2, 3, and 5, or with asthma and eczema at age 5. However, after adjusting for potential confounders, age 5 cockroach-induced PBMC proliferation was associated with anti-cockroach IgE, total IgE, and asthma (p &lt; 0.05).
Conclusion:
In contrast to allergen-induced CBMC proliferation, age 5 cockroach-induced PBMC proliferation was associated with age 5 specific and total IgE, and asthma, in an inner-city cohort where cockroach allergens are prevalent and exposure can be high.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/11</link>
                <dc:creator>Carolyn Chang</dc:creator>
                <dc:creator>Kevin Gauvey-Kern</dc:creator>
                <dc:creator>Alina Johnson</dc:creator>
                <dc:creator>Elizabeth Kelvin</dc:creator>
                <dc:creator>Ginger Chew</dc:creator>
                <dc:creator>Frederica Perera</dc:creator>
                <dc:creator>Rachel Miller</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:11</dc:source>
        <dc:date>2010-08-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-11</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2010-08-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/10">
        <title>Hypoxia modulates human eosinophil function</title>
        <description>Background:
Eosinophils are involved in various inflammatory processes including allergic inflammation during which angiogenesis has been documented. Angiogenesis is most likely connected to the hypoxia which characterizes inflamed tissues. Eosinophils produce VEGF and are pro-angiogenic. However, to the best of our knowledge no study has been performed to verify the existence of a direct link between eosinophils, hypoxia and angiogenesis in allergic inflammation.ObjectiveTo characterize eosinophil function and angiogenic potential under hypoxic conditions.
Methods:
Human peripheral blood eosinophils were cultured in normoxic or hypoxic conditions with or without cytokines. Viability and apoptosis were assessed by Annexin V/PI staining. Anti- or pro-apoptotic protein levels, HIF-1&#945; levels and MAPK phosphorylation were analyzed by immunoblot analysis. Angiogenic mediator release was evaluated by ELISA.
Results:
Hypoxic eosinophils were more viable than normoxic ones after up to three days. In addition in hypoxia, anti-apoptotic Bcl-XL protein levels increased more than pro-apoptotic Bax levels. Hypoxia increased VEGF and IL-8 release. In hypoxic eosinophils high levels of HIF-1&#945; were observed, particularly in the presence of GM-CSF. MAPK, particularly ERK1/2 inhibitors, decreased hypoxia-mediated VEGF release and HIF-1&#945; expression.
Conclusion:
Eosinophils respond to hypoxia by up-regulation of survival and of some of their pro-angiogenic functions indicating a correlation between eosinophilic inflammation and angiogenesis.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/10</link>
                <dc:creator>Alon Nissim Ben Efraim</dc:creator>
                <dc:creator>Ron Eliashar</dc:creator>
                <dc:creator>Francesca Levi-Schaffer</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:10</dc:source>
        <dc:date>2010-07-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-10</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2010-07-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/9">
        <title>IgG transmitted from allergic mothers decreases allergic sensitization in breastfed offspring</title>
        <description>Background:
The mechanism(s) responsible for the reduced risk of allergic disease in breastfed infants are not fully understood. Using an established murine model of asthma, we demonstrated previously that resistance to allergic airway disease transmitted from allergic mothers to breastfed offspring requires maternal B cell-derived factors.ObjectiveThe aim of this study was to investigate the role of offspring neonatal Fc receptor for IgG uptake by intestinal epithelial cells (FcRn) in this breast milk transferred protection from allergy.
Methods:
Allergic airway disease was induced during pregnancy in C57BL/6 female mice. These allergic mothers foster nursed naive FcRn+/- or FcRn-/- progeny born to FcRn+/- females that were mated to C57BL/6J-FcRn-/- male mice. In offspring deficient in FcRn, we expected reduced levels of systemic allergen-specific IgG1, a consequence of decreased absorption of maternal IgG from the lumen of the neonatal gastrointestinal tract. Using this model, we were able to investigate how breast milk IgG affected offspring responses to allergic sensitization.
Results:
Levels of maternal antibodies absorbed from the breast milk of allergic foster mothers were determined in weanling FcRn-sufficient or -deficient mice. Maternal transmission of allergen-specific IgG1 to breastfed FcRn-/- offspring was at levels 103-104 lower than observed in FcRn+/- or FcRn+/+ mice. Five weeks after weaning, when offspring were 8 wk old, mice were sensitized and challenged to evaluate their susceptibility to develop allergic airway disease. Protection, indicated by reduced parameters of disease (allergen-specific IgE in serum, eosinophilic inflammation in the airways and lung) were evident in FcRn-sufficient mice nursed as neonates by allergic mothers. In contrast, FcRn-deficient mice breastfed by the same mothers acquired limited, if any, protection from development of allergen-specific IgE and associated pathology.
Conclusions:
FcRn expression was a major factor in determining how breastfed offspring of allergic mothers acquired levels of systemic allergen-specific IgG1 sufficient to inhibit allergic sensitization in this model.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/9</link>
                <dc:creator>Adam Matson</dc:creator>
                <dc:creator>Roger Thrall</dc:creator>
                <dc:creator>Ektor Rafti</dc:creator>
                <dc:creator>Elizabeth Lingenheld</dc:creator>
                <dc:creator>Lynn Puddington</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:9</dc:source>
        <dc:date>2010-07-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-9</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2010-07-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/8">
        <title>Does improvement management of atopic dermatitis influence the appearance of respiratory allergic diseases? A follow-up study.</title>
        <description>Background:
Atopic dermatitis (AD) is often the prelude to allergic diseases. The aim of this study was 1) to evaluate if an integrated management regime could bring about a change in the evolution of the disease in comparison to the results of a previous study; 2) to determine whether the refinement of allergic investigations allowed to identify more promptly the risk factors of evolution into respiratory allergic diseases.
Methods:
The study included 176 children affected by AD and previously evaluated between 1993 and 2002 at the age of 9-16 months, who underwent a telephonic interview by means of a semi-structured, pre-formed questionnaire after a mean follow-up time of 8 years. According to the SCORAD, at first evaluation children had mild AD in 23% of cases, moderate in 62%, severe in 15%.
Results:
AD disappeared in 92 cases (52%), asthma appeared in 30 (17%) and rhinoconjunctivitis in 48 (27%). The factors significantly related to the appearance of asthma were: sensitization to food allergens with sIgE &gt; 2 KU/L (cow&apos;s milk and hen&apos;s egg; P &lt; 0.05); to inhalant allergens with sIgE &gt; 0.35 KU/L (P &lt; 0.05). Logistic regression analysis showed that inhalant sensitization was positively related to the occurrence of asthma (OR = 4.219). While AD showed similar rates of disappearance to those of our previous study, the incidence of asthma was reduced, at the same follow-up time, from 29% to 15% (P = 0.002), and the incidence of rhinoconjunctivitis from 35% to 24% (P = 0.02).
Conclusion:
Comparing the results with those of the previous study, integrated management of AD does not seem to influence its natural course. Nevertheless, the decrease in the percentage of children evolving towards respiratory allergic disease stresses the importance of early diagnosis and improvement management carried out by specialist centers. The presence of allergic sensitization at one year of age might predict the development of respiratory allergy.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/8</link>
                <dc:creator>Giampaolo Ricci</dc:creator>
                <dc:creator>Annalisa Patrizi</dc:creator>
                <dc:creator>Arianna Giannetti</dc:creator>
                <dc:creator>Arianna Dondi</dc:creator>
                <dc:creator>Barbara Bendandi</dc:creator>
                <dc:creator>Massimo Masi</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:8</dc:source>
        <dc:date>2010-06-30T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-8</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2010-06-30T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/7">
        <title>Recombinant phospholipase A1 (Ves v 1) from yellow jacket venom for improved diagnosis of hymenoptera venom hypersensitivity</title>
        <description>Background:
Hymenoptera venoms are known to cause life-threatening IgE-mediated anaphylactic reactions in allergic individuals. Proper diagnosis of hymenoptera venom allergy using venom extracts is severely affected by molecular cross-reactivities. Although non-glycosylated marker allergens would facilitate the identification of the culprit venom, the major allergen phospholipase A1 (Ves v 1) from yellow jacket venom (YJV) remained unavailable so far.
Methods:
Expression of Ves v 1 as wild type and enzymatically inactivated mutant and Ves v 5 in insect cells yielded soluble proteins that were purified via affinity chromatography. Functionality of the recombinant allergens was assessed by enzymatic and biophysical analyses as well as basophil activation tests. Diagnostic relevance was addressed by ELISA-based analyses of sera of YJV-sensitized patients.
Results:
Both major allergens Ves v 1 and Ves v 5 could be produced in insect cells in secreted soluble form. The recombinant proteins exhibited their particular biochemical and functional characteristics and were capable for activation of human basophils. Assessment of IgE reactivity of sera of YJV-sensitized and double-sensitized patients emphasised the relevance of Ves v 1 in hymenoptera venom allergy. In contrast to the use of singular molecules the combined use of both molecules enabled a reliable assignment of sensitisation to YJV for more than 90% of double-sensitised patients.
Conclusions:
The recombinant availability of Ves v 1 from yellow jacket venom will contribute to a more detailed understanding of the molecular and allergological mechanisms of insect venoms and may provide a valuable tool for diagnostic and therapeutic approaches in hymenoptera venom allergy.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/7</link>
                <dc:creator>Henning Seismann</dc:creator>
                <dc:creator>Simon Blank</dc:creator>
                <dc:creator>Liliana Cifuentes</dc:creator>
                <dc:creator>Ingke Braren</dc:creator>
                <dc:creator>Reinhard Bredehorst</dc:creator>
                <dc:creator>Thomas Grunwald</dc:creator>
                <dc:creator>Markus Ollert</dc:creator>
                <dc:creator>Edzard Spillner</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:7</dc:source>
        <dc:date>2010-04-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-7</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2010-04-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/6">
        <title>Molecular defects in the mannose binding lectin pathway in dermatological disease: Case report and literature review</title>
        <description>Mannose-binding lectin (MBL) and the Mannose-binding lectin-associated serine proteases (MASPs) are an essential aspect of innate immune responses that probably play an important but understudied role in cutaneous function. The MBL-MASP pathway appears to exert its primary role by assisting in the clearance of apoptotic skin cells (thus preventing accumulation and a subsequent autoimmune response) and promoting opsonophagocytosis of invading pathogens, limiting their dissemination. Deficiencies of the pathway have been described and are associated with infectious, autoimmune and vascular complications. However, the role of this pathway in dermatological disease is essentially unexplored. We describe 6 patients presenting with recurrent inflammatory and/or infectious skin conditions who also demonstrated severely low MBL levels. One patient also had a defect in the MASP2 gene. Genotype analysis revealed specific point mutations in the MBL2 promoter in all 6 patients and a variant MASP-2 gene in one patient. Five patients presented recurrent pustular skin infections (cellulitis, folliculitis and cutaneous abscess). A case of Grover&apos;s disease and one forme fruste of Behcet&apos;s syndrome (orogenital ulcers) were also observed. The patients responded to antimicrobial therapy, although in some, recurrence of infection was the rule. It appears that MBL deficiency may contribute to recurrent skin infections and to certain forms of inflammatory skin disease. The mechanisms may relate to the role of this pathway in innate immunity, removal of apoptotic cells and in immune complexes. Further study of MBL pathway defects in dermatological disease is required.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/6</link>
                <dc:creator>Christopher Miller</dc:creator>
                <dc:creator>Sara Wilgenbusch</dc:creator>
                <dc:creator>Mini Michaels</dc:creator>
                <dc:creator>David Chi</dc:creator>
                <dc:creator>George Youngberg</dc:creator>
                <dc:creator>Guha Krishnaswamy</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:6</dc:source>
        <dc:date>2010-03-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-6</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2010-03-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/5">
        <title>Association of IL-4RA single nucleotide polymorphisms, HLA-DR and HLA-DQ in children with Alternaria-sensitive moderate-severe asthma</title>
        <description>Background:
Asthma afflicts 6% to 8% of the United States population, and severe asthma represents approximately 10% of asthmatic patients. Several epidemiologic studies in the United States and Europe have linked Alternaria sensitivity to both persistence and severity of asthma. In order to begin to understand genetic risk factors underlying Alternaria sensitivity and asthma, in these studies we examined T cell responses to Alternaria antigens, HLA Class II restriction and HLA-DQ protection in children with severe asthma.
Methods:
Sixty children with Alternaria-sensitive moderate-severe asthma were compared to 49 children with Alternaria-sensitive mild asthma. We examined HLA-DR and HLA-DQ frequencies in Alternaria-sensitive asthmatic by HLA typing. To determine ratios of Th1/Th2 Alternaria-specific T-cells, cultures were stimulated in media alone, Alternaria alternata extract and Alt a1. Sensitivity to IL-4 stimulation was measured by up-regulation of CD23 on B cells.
Results:
Children with Alternaria-sensitive moderate-severe asthma trended to have increased sensitivities to Cladosporium (46% versus 35%), to Aspergillus (43% versus 28%), and significantly increased sensitivities to trees (78% versus 57%) and to weeds (68% versus 48%). The IL-4RA ile75val polymorphism was significantly increased in Alternaria-sensitive moderate-severe asthmatics, 83% (0.627 allele frequency) compared to Alternaria-sensitive mild asthmatics, 57% (0.388 allele frequency). This was associated with increased sensitivity to IL-4 stimulation measured by significantly increased IL-4 stimulated CD23 expression on CD19+ and CD86+CD19+ B cells of Alternaria-sensitive moderate-severe asthmatics. IL-5 and IL-13 synthesis was significantly increased in Alternaria-sensitive moderate-severe asthmatics compared to mild asthmatics to Alternaria extract and Alt a1 stimulation. The frequency of HLA-DQB1*03 allele was significantly decreased in Alternaria-sensitive moderate-severe asthmatics compared to mild asthmatics, 39% versus 63%, with significantly decreased allele frequency, 0.220 versus 0.398.SummaryIn children with Alternaria-sensitive moderate severe asthma, there was an increased Th2 response to Alternaria stimulation and increased sensitivity to IL-4 stimulation. This skewing towards a Th2 response was associated with an increased frequency of the IL-4RA ile75val polymorphism. In evaluating the HLA association, there was a decreased frequency of HLA-DQB1*03 in Alternaria-sensitive moderate severe asthmatic children consistent with previous studies suggest that HLA-DQB1*03 may be protective against the development of mold-sensitive severe asthma.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/5</link>
                <dc:creator>Alan Knutsen</dc:creator>
                <dc:creator>Hari Vijay</dc:creator>
                <dc:creator>Barbara Kariuki</dc:creator>
                <dc:creator>Luis Santiago</dc:creator>
                <dc:creator>Ralph Graff</dc:creator>
                <dc:creator>Jonathan Wofford</dc:creator>
                <dc:creator>Maulik Shah</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:5</dc:source>
        <dc:date>2010-03-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-5</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2010-03-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/4">
        <title>Lack of neo-sensitization to Pen a 1 in patients treated with mite sublingual immunotherapy</title>
        <description>Background:
Some studies reported the possible induction of food allergy, caused by neo-sensitization to cross-reacting allergens, during immunotherapy with aeroallergens, while other studies ruled out such possibility.ObjectivesThe aim of this study was to evaluate the development of neo-sensitization to Pen a 1 (tropomyosin) as well as the appearance of reactions after ingestion of foods containing tropomyosin as a consequence of sublingual mite immunization.Materials and methodsSpecific IgE to Tropomyosin (rPen a 1) before and after mite sublingual immunotherapy in 134 subjects were measured. IgE-specific antibodies for mite extract and recombinant allergen Pen a 1 were evaluated using the immunoenzymatic CAP system (Phadia Diagnostics, Milan, Italy).
Results:
All patients had rPen a 1 IgE negative results before and after mite SLIT and did not show positive shrimp extract skin reactivity and serological rPen a 1 IgE conversion after treatment. More important, no patient showed systemic reactions to crustacean ingestion.
Conclusions:
Patients did not show neo-sensitization to tropomyosin, a component of the extract (namely mite group 10) administered. An assessment of a patient&apos;s possible pre-existing sensitisation to tropomyosin by skin test and/or specific IgE prior to start mite extract immunotherapy is recommended.Trial RegistrationThis trial is registered in EudraCT, with the ID number of 2010-02035531.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/4</link>
                <dc:creator>Renato Rossi</dc:creator>
                <dc:creator>Giorgio Monasterolo</dc:creator>
                <dc:creator>Cristoforo Incorvaia</dc:creator>
                <dc:creator>Philippe Moingeon</dc:creator>
                <dc:creator>Franco Frati</dc:creator>
                <dc:creator>Giovanni Passalacqua</dc:creator>
                <dc:creator>Lucilla Rossi</dc:creator>
                <dc:creator>Giorgio Canonica</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:4</dc:source>
        <dc:date>2010-03-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-4</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2010-03-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.clinicalmolecularallergy.com/content/8/1/3">
        <title>Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective</title>
        <description>Background:
Altered levels of Immunoglobulin E (IgE) represent a dysregulation of IgE synthesis and may be seen in a variety of immunological disorders. The object of this review is to summarize the historical and molecular aspects of IgE synthesis and the disorders associated with dysregulation of IgE production.
Methods:
Articles published in Medline/PubMed were searched with the keyword Immunoglobulin E and specific terms such as class switch recombination, deficiency and/or specific disease conditions (atopy, neoplasia, renal disease, myeloma, etc.). The selected papers included reviews, case reports, retrospective reviews and molecular mechanisms. Studies involving both sexes and all ages were included in the analysis.
Results:
Both very low and elevated levels of IgE may be seen in clinical practice. Major advancements have been made in our understanding of the molecular basis of IgE class switching including roles for T cells, cytokines and T regulatory (or Treg) cells in this process. Dysregulation of this process may result in either elevated IgE levels or IgE deficiency.
Conclusion:
Evaluation of a patient with elevated IgE must involve a detailed differential diagnosis and consideration of various immunological and non-immunological disorders. The use of appropriate tests will allow the correct diagnosis to be made. This can often assist in the development of tailored treatments.</description>
        <link>http://www.clinicalmolecularallergy.com/content/8/1/3</link>
                <dc:creator>Mariah Pate</dc:creator>
                <dc:creator>John Smith</dc:creator>
                <dc:creator>David Chi</dc:creator>
                <dc:creator>Guha Krishnaswamy</dc:creator>
                <dc:source>Clinical and Molecular Allergy 2010, 8:3</dc:source>
        <dc:date>2010-02-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-7961-8-3</dc:identifier>
        <prism:publicationName>Clinical and Molecular Allergy</prism:publicationName>
        <prism:issn>1476-7961</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-02-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
